Department of Oncology, Affiliated Hospital of Guangdong Medical College, Zhanjiang, China.
Cancer Invest. 2011 Feb;29(2):107-12. doi: 10.3109/07357907.2010.543211.
Even less than a decade since the discovery of TSLC1, overwhelming evidence demonstrates that the loss of TSLC1 expression by methylation-mediated epigenetic silencing or LOH is crucially implicated in various processes during tumorigenesis. Here, we summarize TSLC1 function, highlighting the concept that TSLC1 mediates the formation of tumor suppressor network via its multidomain structure and bridges extracellular adhesive activity with intracellular signaling. Next, we focus on the histopathology of TSLC1 in various cancers and the association with clinicopathological characteristics. On the basis of these, we propose that TSLC1 represents a promising biomarker for cancer diagnosis and a potential target for cancer therapy.
自 TSLC1 被发现以来，还不到十年的时间，大量证据表明，TSLC1 的表达缺失是通过甲基化介导的表观遗传沉默或 LOH 导致的，这与肿瘤发生过程中的各种过程密切相关。在这里，我们总结了 TSLC1 的功能，强调了 TSLC1 通过其多结构域结构介导肿瘤抑制网络的形成，并将细胞外黏附活性与细胞内信号联系起来的概念。接下来，我们重点介绍了 TSLC1 在各种癌症中的组织病理学表现及其与临床病理特征的关联。在此基础上，我们提出 TSLC1 是一种有前途的癌症诊断生物标志物和癌症治疗的潜在靶点。
